oral testimony to the fda advisory committee on the approval of amx0035
Published 2 years ago • 343 plays • Length 3:49Download video MP4
Download video MP3
Similar videos
-
2:39
oral testimony to the fda advisory committee on the approval of tofersen
-
11:30
amx0035 approved
-
0:58
#approveamx0035
-
30:04
why fda decision on tofersen matters
-
35:55
webinar: amx0035 results - implications for people with als
-
55:24
challenges in drug development for als
-
25:47
tofersen and the future of als drug development
-
57:05
tofersen and the fda approval process
-
58:18
amylyx's als drug amx0035 shows promising phase 2/3 clinical trial results
-
2:31
treatment updates in als: edaravone, amx0035, and tofersen
-
0:45
fda approves new drug to slow progress of als
-
18:16
pre-operative evaluation and peri-operative management of people living with als
-
29:46
"expediting access to a promising new als drug…"
-
2:42
fda panel votes against recommending new als drug, for now
-
1:02:10
navigating the challenges of caregiving for people living with als
-
1:35
2021 clinical research forum | the centaur trial for als
-
2:39
new drug research: tofacitinib & als
-
0:41
dr. dinardo on the fda approval of oral azacitidine in aml
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml